Shares in Suven Lifesciences jumped more than 8 per cent after the company secured product patent from countries like China, Mexico, Israel, China, Singapore and Sri Lanka. The product patent is corresponding to their new chemical entities (NCEs) for the treatment of disorders associated with Neuro degenerative diseases.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" says Venkat Jasti, CEO of Suven.

The shares were last trading at Rs 224, up 8.61 per cent over Thursday's close.

GoodReturns.in